Doseology Sciences, Inc. (TSE:MOOD)
:MOOD
Top Page
Doseology Sciences
(MOOD)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.54
▲(1.13% Upside)
Action:ReiteratedDate:03/18/26
The score is held down primarily by weak financial performance (low/declining revenue, sizable losses, and negative cash flow that may require external financing). Technicals also lean bearish with price below key moving averages and a slightly negative MACD. Valuation provides limited support because the negative P/E reflects unprofitability and there is no dividend yield.
Positive Factors
Balance sheet strength (low debt)
Doseology’s near-zero debt and equity that exceeds total assets materially reduce leverage risk and preserve financing flexibility. Over 2–6 months this structural strength lowers bankruptcy risk and gives management optionality to raise capital or invest without immediate solvency pressure.
Negative Factors
Small, volatile revenue base
Very small and volatile revenues undermine predictability of margins and scale economics; a 27% decline year-over-year shows revenue instability. Over months this raises execution risk, makes fixed-cost absorption harder, and weakens prospects for durable profitable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength (low debt)
Doseology’s near-zero debt and equity that exceeds total assets materially reduce leverage risk and preserve financing flexibility. Over 2–6 months this structural strength lowers bankruptcy risk and gives management optionality to raise capital or invest without immediate solvency pressure.
Read all positive factors
Doseology Sciences (MOOD) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.41M
Dividend YieldN/A
Average Volume (3M)1.79K
Price to Earnings (P/E)―
Beta (1Y)-3.38
Revenue Growth-50.89%
EPS Growth-32.33%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding8,011,621
10 Day Avg. Volume3,383
30 Day Avg. Volume1,793
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)3.46
Price to Sales (P/S)113.73
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Doseology Sciences Business Overview & Revenue Model
Company Description
Doseology Sciences Inc. engages in the cultivation and extraction of nutraceutical and pharmaceutical products in Canada. It focuses on research, development, and sale of medicinal mushroom products, including tinctures and powders. The company se...
How the Company Makes Money
null...
Doseology Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.56K | 98.52K | 43.09K | 16.05K | 0.00 |
| Gross Profit | 18.89K | 72.09K | 41.29K | -148.38K | -92.83K |
| EBITDA | -471.61K | -319.48K | -1.78M | -1.72M | -1.47M |
| Net Income | -447.79K | -339.85K | -1.78M | -1.94M | -1.63M |
Balance Sheet | |||||
| Total Assets | 1.49M | 1.10M | 1.40M | 3.87M | 5.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.43M | 1.06M | 1.30M | 1.87M | 3.73M |
| Total Debt | 0.00 | 0.00 | 50.27K | 746.10K | 687.54K |
| Total Liabilities | 94.11K | 82.49K | 99.19K | 871.51K | 3.41M |
| Stockholders Equity | 1.40M | 1.02M | 1.30M | 3.00M | 2.58M |
Cash Flow | |||||
| Free Cash Flow | -342.24K | -235.12K | -481.05K | -1.72M | -2.54M |
| Operating Cash Flow | -342.24K | -235.12K | -481.05K | -1.71M | -2.37M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -7.88K | -26.05K |
| Financing Cash Flow | 711.68K | -6.14K | -91.88K | -140.08K | 5.79M |
Doseology Sciences Technical Analysis
Negative
0.53
Price Trends
0.69
Negative
0.66
Negative
0.69
Negative
Market Momentum
-0.03
Positive
44.81
Neutral
1.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MOOD, the sentiment is Negative. The current price of 0.53 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.69, and below the 200-day MA of 0.69, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 44.81 is Neutral, neither overbought nor oversold. The STOCH value of 1.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MOOD.
Doseology Sciences Peers Comparison
UnderperformOutperform
Sector (51)
TSE:MOOD
Doseology Sciences
0.55
0.18
48.65%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.10
-47.50%
TSE:ENBI
Entheon Biomedical
0.10
-0.04
-31.03%
TSE:MYND
MYND Life Sciences
0.07
0.04
133.33%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
1.26
-2.74
-68.50%
Doseology Sciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A Transactions
Doseology Uplists to OTCQB to Advance Growth in Oral Stimulant Pouch Market
Positive
Mar 11, 2026
Doseology Sciences Inc. has uplisted its common shares to the OTCQB Venture Market in the United States under the symbol DOSEF, a move aimed at expanding access for U.S. investors and aligning the company with higher standards of financial reporti...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
Doseology debuts nicotine-free energy pouches in U.S. direct-to-consumer pilot
Positive
Mar 4, 2026
Doseology Sciences has launched its Feed That Brain Energy Pouches in the U.S. through its first direct-to-consumer pilot, offering nicotine-free, caffeine-based oral stimulant pouches via its own website and Amazon. The product aims to deliver co...
Business Operations and StrategyExecutive/Board Changes
Doseology Taps Veteran Pharmacy Executive Larry Latowsky as Executive Chairman to Steer Commercial Expansion
Positive
Feb 20, 2026
Doseology Sciences has appointed veteran retail and healthcare executive Larry Latowsky as a director and Executive Chairman of its board, signaling a governance and leadership upgrade as it prepares to scale its precision-controlled oral stimulan...
Business Operations and StrategyProduct-Related Announcements
Doseology Launches Pilot for Caffeine Energy Pouches Under Feed That Brain Brand
Positive
Jan 21, 2026
Doseology Sciences has begun a pilot production run of non-nicotine, caffeine-based energy pouches under its Feed That Brain brand, positioning the platform at the center of its broader oral stimulant strategy. The initiative is designed as a cont...
Business Operations and StrategyRegulatory Filings and Compliance
Doseology Boosts Transparency With New Annual Information Form Filing
Positive
Jan 16, 2026
Doseology Sciences Inc. has filed its Annual Information Form for the fiscal year ended June 30, 2025 on SEDAR+, consolidating its business, strategy, risk factors, governance practices, and capital structure into a single, structured disclosure d...
Business Operations and Strategy
Doseology Taps McKinney Advisors to Fast-Track Regulatory Path for Oral Pouch Line
Positive
Jan 12, 2026
Doseology Sciences has entered a strategic partnership with McKinney Regulatory Science Advisors to accelerate the regulatory and commercial development of its innovative oral pouch products. The engagement is designed to fast-track the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.